

LEUKOCARE presenting at the 24th European Hematology Congress in Amsterdam

LEUKOCARE AG to present at the European Hematology Congress highlighting effective stabilization of viral vectors in liquid using LEUKOCARE's algorithm-based development approach.

Munich, Germany, 11 June 2019

Munich-based biotechnology company LEUKOCARE announced today that it will present at the European Hematology Congress in Amsterdam featuring the effective stabilization of viral vectors in liquid using LEUKOCARE's database-driven and algorithm-based development approach.

"We are pleased that our data has been accepted for presentation at the 24th EHA Congress, thus giving us the opportunity to present and share data for the first time at one of the top-class global haematology events, where gene and cell therapy has become an increasingly dominant role," stated Michael Scholl, CEO with LEUKOCARE. "Successful development of liquid formulations of viral vectors stable at 2-8°C for gene therapy products or in CAR-T processes could be a paradigm shift. The prevention of virus activity during freeze/thaw, lyophilisation and storage will substantially reduce manufacturing and supply costs for these therapies."

Following is the accepted presentation featuring LEUKOCARE at the 24th European Hematology Congress:

LEUKOCARE AG: Effective Stabilization of viral vectors in liquid using an algorithm-based development approach; presented by Dr Eva Reinauer on Friday, June 14

For more information, please visit:

<https://library.ehaweb.org/eha/2019/24th/266248/eva.reinauer.effective.stabilization.of.viral.vectors.in.liquid.using.an.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dpf448>

About LEUKOCARE AG

LEUKOCARE provides a next-generation formulation technology platform for the protection of proteins like biopharmaceuticals to allow the development of better products. The proprietary Stabilizing and Protecting Solutions (SPS[®]) technologies are provided to development projects of partners in the pharmaceutical and medical device industry. LEUKOCARE's SPS[®] technologies improve stability and quality of biologics like antibodies, vaccines etc. in dry and liquid formulation including high-concentration formulations. SPS[®] technologies also protect proteins in biologically functionalized combination devices.

www.leukocare.com

Contact:
Michael Scholl
michael.scholl@leukocare.com
+49 (0) 89 7801 6650